Abstract
AbstractBackgroundBlood proteins are emerging candidate biomarkers for Alzheimer’s disease (AD). A comprehensive investigation of the AD blood proteome will help identify additional biomarkers to delineate the disease’s pathways and define specific AD stages.MethodWe quantified 1,160 plasma proteins in a Hong Kong Chinese cohort (n = 106 AD patients, n = 74 healthy controls) by high‐throughput proximity extension assay to identify AD‐associated plasma proteins.ResultPlasma proteins involved in diverse biological processes were found to be dysregulated in AD. A subset of plasma proteins was selected to represent the AD plasma protein profile, which formed the basis of a scoring system that can accurately classify AD and associated endophenotypes. In addition, we showed that certain plasma proteins and biological processes exhibit stage‐specific dysregulation in AD, thus adding biological annotations to AD stages.ConclusionThis study comprehensively profiled the AD plasma proteome and serves as a foundation for a high‐performance, blood‐based test for clinical AD screening and staging.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
